FDA Approves Roche’s HER2 Companion Diagnostic for Biliary Tract Cancer Treatment
The PATHWAY HER2 test is a CDx for HER2-positive biliary tract cancer for targeted treatment with Jazz Pharmaceuticals’ ZIIHERA.
Read MorePosted by Andy Lundin | Nov 25, 2024 | Unknown Origin & Other Cancer Types |
The PATHWAY HER2 test is a CDx for HER2-positive biliary tract cancer for targeted treatment with Jazz Pharmaceuticals’ ZIIHERA.
Read MorePosted by Andy Lundin | Nov 21, 2024 | Molecular Diagnostics |
Delve Bio found that mNGS identified more pathogens from cerebrospinal fluid samples than all conventional diagnostic methods combined.
Read MorePosted by Chris Wolski | Nov 18, 2024 | Disease States |
Discovering mutations in the FLVCR1 gene, provided a genetic diagnosis for 30 individuals with previously undiagnosed conditions.
Read MorePosted by Chris Wolski | Nov 18, 2024 | Lab Automation |
Artificial Intelligence enables development of new diagnostic and prognostic models, supporting the move toward personalized medicine.
Read MorePosted by Andy Lundin | Nov 14, 2024 | Molecular Diagnostics |
A research team developed a new method for detecting low-abundance proteins in plasma, enhancing early disease detection.
Read More